1-ethyl-5-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-N-(oxan-4-yl)pyrazolo[3,4-b]pyridin-4-amine | 720704-21-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-ethyl-5-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-N-(oxan-4-yl)pyrazolo[3,4-b]pyridin-4-amine
• CAS: 720704-21-2
• 化学式: C₂₁H₂₁FN₆O₂
• 分子量: 408.435
• InChiKey: ZENDFWOFRUOXDJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  90.9
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.75h， 生成 1-ethyl-5-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-N-(oxan-4-yl)pyrazolo[3,4-b]pyridin-4-amine
  参考文献：
  名称：

  Pyrazolopyridines as potent PDE4B inhibitors: 5-Heterocycle SAR

  摘要：

  Following the discovery of 4-(substituted amino)-1-alkyl-pyrazolo[3,4-b]pyridine-5-carboxamides as potent and selective phosphodiesterase 4B inhibitors, [Hamblin, J. N.; Angell, T.; Ballentine, S., et al. Bioorg. Med. Chem. Lett. 2008, 18, 4237] the SAR of the 5-position was investigated further. A range of substituted heterocycles showed good potencies against PDE4. Optimisation using X-ray crystallography and computational modelling led to the discovery of 16, with sub-nM inhibition of LPS-induced TNF-alpha production from isolated human peripheral blood mononuclear cells. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.136

文献信息

• Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
  申请人：Allen George David

  公开号：US20060252790A1

  公开（公告）日：2006-11-09

  The invention relates to a compound of formula (I) or a salt thereof: wherein: R 1 is C 1-4 alkyl, C 1-3 fluoroalkyl or —(CH 2 ) 2 OH; R 2 is a hydrogen atom (H), methyl or C 1 fluoroalkyl; R 3a is a hydrogen atom (H) or C 1-3 alkyl; R 3 is optionally substituted branched C 3-6 alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted mono-unsaturated-C 5-7 cycloalkenyl, optionally substituted phenyl, or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc): in which n 1 and n 2 independently are 1 or 2; and Y is O, S, SO 2 , or NR 4 ; and wherein Het is of sub-formula (i), (ii), (iii), (iv) or (v): The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis.

  本发明涉及式（I）化合物或其盐： 其中：R1是C1-4烷基，C1-3氟代烷基或—（CH2）2OH；R2是氢原子（H），甲基或C1氟代烷基；R3a是氢原子（H）或C1-3烷基；R3是可选的取代的支链C3-6烷基，可选的取代的C3-8环烷基，可选的取代的单不饱和C5-7环烯基，可选的取代的苯基，或者是亚式（aa），（bb）或（cc）的可选取代的杂环基： 其中n1和n2独立地为1或2；Y是O，S，SO2或NR4；而Het是亚式（i），（ii），（iii），（iv）或（v）： 这些化合物是磷酸二酯酶（PDE）抑制剂，特别是PDE4抑制剂。还提供了使用式（I）化合物或其药学上可接受的盐制造药物，用于治疗和/或预防哺乳动物（例如人类）的炎症和/或过敏性疾病，例如慢性阻塞性肺疾病（COPD），哮喘或过敏性鼻炎。
• PYRAZOLO¬3,4-B PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1581532B1

  公开（公告）日：2010-04-28
• US7528148B2
  申请人：——

  公开号：US7528148B2

  公开（公告）日：2009-05-05
• Pyrazolopyridines as potent PDE4B inhibitors: 5-Heterocycle SAR
  作者：Charlotte J. Mitchell、Stuart P. Ballantine、Diane M. Coe、Caroline M. Cook、Christopher J. Delves、Mike D. Dowle、Chris D. Edlin、J. Nicole Hamblin、Stuart Holman、Martin R. Johnson、Paul S. Jones、Sue E. Keeling、Michael Kranz、Mika Lindvall、Fiona S. Lucas、Margarete Neu、Yemisi E. Solanke、Don O. Somers、Naimisha A. Trivedi、Joanne O. Wiseman

  DOI：10.1016/j.bmcl.2010.07.136

  日期：2010.10

  Following the discovery of 4-(substituted amino)-1-alkyl-pyrazolo[3,4-b]pyridine-5-carboxamides as potent and selective phosphodiesterase 4B inhibitors, [Hamblin, J. N.; Angell, T.; Ballentine, S., et al. Bioorg. Med. Chem. Lett. 2008, 18, 4237] the SAR of the 5-position was investigated further. A range of substituted heterocycles showed good potencies against PDE4. Optimisation using X-ray crystallography and computational modelling led to the discovery of 16, with sub-nM inhibition of LPS-induced TNF-alpha production from isolated human peripheral blood mononuclear cells. (C) 2010 Elsevier Ltd. All rights reserved.